Eli Lilly and (LLY) Given a $80.00 Price Target at Credit Suisse Group

Credit Suisse Group set a $80.00 target price on Eli Lilly and (NYSE:LLY) in a research note released on Sunday morning. The brokerage currently has a hold rating on the stock.

Other equities research analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Eli Lilly and from a hold rating to a buy rating and set a $85.00 price target on the stock in a report on Tuesday, April 3rd. Jefferies Group set a $100.00 price target on shares of Eli Lilly and and gave the company a buy rating in a report on Tuesday, January 16th. Argus raised shares of Eli Lilly and from a hold rating to a buy rating and upped their target price for the stock from $85.52 to $115.00 in a report on Friday, January 5th. JPMorgan Chase set a $105.00 target price on shares of Eli Lilly and and gave the stock a buy rating in a report on Monday, February 26th. Finally, HC Wainwright reaffirmed a buy rating on shares of Eli Lilly and in a report on Wednesday, April 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $93.16.

How to Become a New Pot Stock Millionaire

Shares of Eli Lilly and stock opened at $79.06 on Friday. The firm has a market capitalization of $86,617.97, a price-to-earnings ratio of 18.47, a price-to-earnings-growth ratio of 1.44 and a beta of 0.26. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.01 and a current ratio of 1.32. Eli Lilly and has a 52-week low of $73.69 and a 52-week high of $89.09.



Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.06. The firm had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.95 EPS. analysts expect that Eli Lilly and will post 4.88 EPS for the current fiscal year.

In other Eli Lilly and news, SVP Susan Mahony sold 22,544 shares of the company’s stock in a transaction dated Monday, April 16th. The shares were sold at an average price of $80.09, for a total transaction of $1,805,548.96. Following the transaction, the senior vice president now directly owns 45,652 shares in the company, valued at approximately $3,656,268.68. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Jeffrey N. Simmons sold 9,625 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.12, for a total transaction of $780,780.00. Following the transaction, the senior vice president now owns 152,120 shares in the company, valued at $12,339,974.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 42,970 shares of company stock worth $3,444,557. Corporate insiders own 0.11% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its position in Eli Lilly and by 1.2% during the 4th quarter. BlackRock Inc. now owns 63,854,112 shares of the company’s stock valued at $5,393,119,000 after purchasing an additional 776,893 shares during the period. Franklin Resources Inc. lifted its position in Eli Lilly and by 2.7% during the 4th quarter. Franklin Resources Inc. now owns 28,519,524 shares of the company’s stock valued at $2,408,787,000 after purchasing an additional 754,681 shares during the period. Janus Henderson Group PLC lifted its position in Eli Lilly and by 16.1% during the 3rd quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock valued at $928,719,000 after purchasing an additional 1,503,918 shares during the period. Geode Capital Management LLC lifted its position in Eli Lilly and by 4.3% during the 4th quarter. Geode Capital Management LLC now owns 9,854,964 shares of the company’s stock valued at $830,522,000 after purchasing an additional 406,812 shares during the period. Finally, UBS Asset Management Americas Inc. lifted its position in Eli Lilly and by 1.8% during the 4th quarter. UBS Asset Management Americas Inc. now owns 6,636,386 shares of the company’s stock valued at $560,509,000 after purchasing an additional 115,499 shares during the period. Institutional investors own 77.69% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://stocknewstimes.com/2018/04/23/eli-lilly-and-lly-given-a-80-00-price-target-at-credit-suisse-group.html.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply